NEW YORK (AP) _ Stemline Therapeutics Inc. (STML) on Tuesday reported a loss of $15.5 million in its second quarter.
On a per-share basis, the New York-based company said it had a loss of 66 cents.
The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 48 cents per share.
The biopharmaceutical company posted revenue of $299,400 in the period. Its adjusted revenue was $299,000.
Stemline Therapeutics shares have declined 17 percent since the beginning of the year. The stock has climbed 18 percent in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on STML at https://www.zacks.com/ap/STML
Keywords: Stemline Therapeutics, Earnings Report